Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Martínez, A. Milinkovic, E. Buira, E. De Lazzari, A. León, M. Larrousse, et al.
Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
HIV Medicine, 8 (2007), pp. 251-258
[2.]
C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet, D. Costagliola, et al.
Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic).
J Acquir Immune Defi c Syndr, 48 (2008), pp. 590-598
[3.]
J.S. Currier, M.A. Kendall, W.K. Henry, B. Alston-Smith, F.J. Torriani, P. Tebas, et al.
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.
AIDS, 21 (2007), pp. 1137-1145
[4.]
A.M. Lebech, N. Wiinberg, U.S. Kristoffersen, et al.
Carotid intima-media thickness in HIV patients treated with antiretroviral therapy.
Clin Physiol Funct Imaging, 27 (2007), pp. 173-179
[5.]
F.J. Torriani, L. Komarow, R.A. Parker, B.R. Cotter, J.S. Currier, M.P. Dubè, et al.
Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy.
J Am Coll Cardiol, 52 (2008), pp. 569-576
[6.]
Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
CD4+ count-guided interruption of antiretroviral treatment.
N Engl J Med, 355 (2006), pp. 2283-2296
[7.]
K. Henry, H. Melroe, J. Huebsch, J. Hermundson, C. Levine, L. Swensen, et al.
Severe premature coronary artery disease with protease inhibitors.
Lancet, 351 (1998), pp. 1328
[8.]
S.A. Riddler, E. Smit, S.R. Cole, R. Li, J.S. Chmiel, A. Dobs, et al.
Impact of HIV infection and HAART on serum lipids in men.
JAMA, 289 (2003), pp. 2978-2982
[9.]
H. Murata, P.W. Hruz, M. Mueckler.
The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
J Biol Chem, 275 (2000), pp. 20251-20254
[10.]
R.M. Blümer, M.G. Van Vonderen, J. Sutinen, E. Hassink, M. Ackermans, M.A. Van Agtmael, et al.
Zidovudine/lamivudine contributes to insulin resistence within 3 months of starting combination antiretroviral therapy.
AIDS, 22 (2008), pp. 227-236
[11.]
J.C. Shlay, G. Bartsch, G. Peng, J. Wang, C. Grunfeld, C.L. Gibert, et al.
Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.
J Acquir Immune Defic Syndr, 44 (2007), pp. 506-517
[12.]
T.T. Brown, X. Li, S.R. Cole, L.A. Kingsley, F.J. Palella, S.A. Riddler, et al.
Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.
AIDS, 19 (2005), pp. 1375-1383
[13.]
B. Ledergerber, H. Furrer, M. Rickenbach, R. Lehmann, L. Elzi, B. Hirschel, et al.
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
Clin Infect Dis, 45 (2007), pp. 111-119
[14.]
S. De Wit, C.A. Sabin, R. Weber, S.W. Worm, P. Reiss, C. Cazanave, et al.
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Diabetes Care, 31 (2008), pp. 1224-1229
[15.]
D:A:D Study Group.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi- cohort collaboration.
Lancet, 371 (2008), pp. 1417-1426
[16.]
Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
AIDS, 22 (2008), pp. F17-F24
[17.]
C.H. Brothers, J.E. Hernández, A.G. Cutrell, et al.
Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
J Acquir Immune Defi c Syndr, 51 (2009), pp. 20-28
[18.]
Benson C, Ribaudo H, Zheng E, Koletar S, Smurzynski M, Bosch R, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG a5001. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, 2009. Abstract 721.
[19.]
Costagliola D. The current debate on abacavir; risks and relationship between HIV viremia and cardiovascular events. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, July 19-22, 2009. Invited lecture MOAB201.
[20.]
Bedimo R, Westfall A, Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, July 19-22, 2009. Abstract MOAB202.
[21.]
Martínez E, Larrousse M, Pérez I, et al. No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN61891868). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, July 19-22, 2009. Abstract MOAB203.
[22.]
Press Release. Meeting highlights from the Committee for Medicinal Products for Human Use, 20-23 April 2009. Disponible en: http://www.emea.europa.eu/pdfs/human/press/pr/24966009en.pdf
[23.]
M.G. Law, N. Friis-Møller, W.M. El-Sadr, R. Weber, P. Reiss, A. D’Arminio Monforte, et al.
The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D:A:D Study.
HIV Med, 7 (2006), pp. 218-230
Copyright © 2009. Elsevier España S.L.. Todos los derechos reservados
